Insulin infusion systems
Search documents
3 Reasons Why Growth Investors Shouldn't Overlook Insulet (PODD)
ZACKS· 2025-11-07 18:46
Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying the right ones can be challenging due to associated risks and volatility [1] Earnings Growth - Insulet has a historical EPS growth rate of 147.8%, with projected EPS growth of 43.8% this year, significantly outperforming the industry average of 13.5% [5] Cash Flow Growth - Insulet's year-over-year cash flow growth stands at 17.4%, well above the industry average of 2.5%. The company's annualized cash flow growth rate over the past 3-5 years is 51.1%, compared to the industry average of 8.2% [6][7] Earnings Estimate Revisions - There has been a positive trend in earnings estimate revisions for Insulet, with the Zacks Consensus Estimate for the current year increasing by 0.5% over the past month [9] Overall Positioning - Insulet holds a Zacks Rank of 2 and a Growth Score of A, indicating strong potential for outperformance in the growth stock category [11]
Is Insulet (PODD) a Solid Growth Stock? 3 Reasons to Think "Yes"
ZACKS· 2025-10-07 17:45
Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the trad ...